Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sun Dec 18 13:41:38 UTC 2022
by
admin
on
Sun Dec 18 13:41:38 UTC 2022
|
| Protein Type | ENZYME |
| Protein Sub Type | SERINE/THREONINE-PROTEIN KINASE |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
U7FKT8J0J3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
P15056
Created by
admin on Sun Dec 18 13:41:40 UTC 2022 , Edited by admin on Sun Dec 18 13:41:40 UTC 2022
|
PRIMARY | |||
|
U7FKT8J0J3
Created by
admin on Sun Dec 18 13:41:40 UTC 2022 , Edited by admin on Sun Dec 18 13:41:40 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET |
In contrast to approved therapies targeting Class I V600E BRAF mutant tumors, KIN-2787 was active across all classes of BRAF-altered melanoma cells.
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
IC50
|
||
|
RADIOLIGAND->TARGET |
A serine/threonine kinase PET
imaging agent for the melanomas mainly in the specific expression of the BRAFV600E mutation.
|
||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
An ATP competitive inhibitor. Binding assay
COMPETITIVE INHIBITOR
IC50
|
||
|
INHIBITOR -> TARGET |
PRECLINICAL
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|